

Agios receives nod for ivosidenib

23 July 2018 | News

Orphan Drug-tagged ivosidenib, an orally available IDH1 inhibitor, had Fast Track status.



Singapore – The FDA approves Agios Pharmaceuticals' TIBSOVO (ivosidenib) for the treatment of adult patients with relapsed/refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation.

Orphan Drug-tagged ivosidenib, an orally available IDH1 inhibitor, had Fast Track status.